A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 2)
| Status: | Terminated |
|---|---|
| Conditions: | Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | December 2007 |
| End Date: | March 2010 |
A Phase 1/2, Ascending Multiple-Dose Study to Evaluate the Safety, Efficacy and Pharmacokinetics of BMS-753493 in Subjects With Advanced Cancer (Schedule 2)
The purpose of this clinical research study is to study the safety of Epofolate (BMS-753493)
in patients with advanced cancers (in Phase 1 portion) and to determine whether Epofolate
(BMS-753493) can shrink or slow the growth of the cancer in patients with advanced ovarian,
renal or breast cancer (in Phase 2 portion)
in patients with advanced cancers (in Phase 1 portion) and to determine whether Epofolate
(BMS-753493) can shrink or slow the growth of the cancer in patients with advanced ovarian,
renal or breast cancer (in Phase 2 portion)
Inclusion Criteria:
- Advanced cancer, excluding cancer in the blood
- Availability of 10 tumor tissue slides
Exclusion Criteria:
- Known brain metastases
- Severe nerve damage
- Significant cardiovascular disease
- Inadequate blood counts
- Inadequate liver or kidney function
- Inadequate thyroid function or uncontrolled thyroid disease
We found this trial at
2
sites
Click here to add this to my saved trials
